Kyle D Holen
Affiliation: University of Wisconsin
- The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitorKyle Holen
University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University Hospital and Clinics, 600 Highland Ave K4 528, Madison, WI 53792, USA
Invest New Drugs 26:45-51. 2008..FK866 is a potent inhibitor or NAD synthesis. This first-in-human study was performed to determine the maximum-tolerated dose, toxicity profile, and pharmacokinetics on a 96-h continuous infusion schedule...
- A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumorsKyle Holen
University of Wisconsin Carbone Cancer Center, 600 Highland Ave, Madison, WI 53792 5666, USA
Invest New Drugs 30:1088-95. 2012..This phase I trial examined safety, tolerability, dose-limiting toxicity (DLT), maximum tolerated dose (MTD), pharmacokinetic parameters, and anti-tumor activity of MK-0731, a potent inhibitor of KSP...
- A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II doseKyle D Holen
University of Wisconsin Carbone Cancer Center, K4 528, 600 Highland Ave, Madison, WI 53792 5666, USA
Cancer Chemother Pharmacol 67:447-54. 2011....
- The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumorsBrian S Choi
University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, WI, 53792, USA
Cancer Chemother Pharmacol 66:973-80. 2010..This study was conducted to determine the toxicity and antitumor activity of 3-AP with irinotecan. Correlative studies included pharmacokinetics and the effects of ABCB1 and UGT1A1 polymorphisms...
- A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumorsTrevor W Dennie
University of Wisconsin Carbone Cancer Center, Madison, USA
Clin Colorectal Cancer 10:57-62. 2011..Lapatinib has already been approved by the US Food and Drug Administration for treatment of selected cases of breast cancer...
- A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancerSam J Lubner
University of Wisconsin Carbone Cancer Center, Madison, USA
Clin Colorectal Cancer 9:157-61. 2010..This phase II study explores the efficacy and safety of a 2-day course of oxaliplatin/capecitabine (2DOC), with oxaliplatin given on day 1 and capecitabine given orally every 8 hours in high doses over 6 doses, mimicking FOLFOX6...
- Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignanciesSteven Attia
University of Wisconsin Paul P Carbone Comprehensive Cancer Center Madison, Madison, WI 53792, USA
Cancer Chemother Pharmacol 64:45-51. 2009..To define dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of capecitabine with fixed-dose rate (FDR) gemcitabine...
- A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinomaTabraiz A Mohammed
D O, M S, University of Wisconsin Hospital and Clinics, 600 Highland Avenue, Madison, Wisconsin 53792, USA
Oncologist 16:835-43. 2011..Thus, this study aimed to evaluate the role of VPA in treating NETs and to determine whether VPA induced the Notch signaling pathway signaling in vivo...
- Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genesJill M Kolesar
University of Wisconsin Carbone Comprehensive Cancer Center, 600 Highland Avenue, K4 554 CSC, Madison, WI, 53792, USA
Cancer Chemother Pharmacol 72:661-7. 2013..Vorinostat is a small molecule inhibitor of class I and II histone deacetylase enzymes which alters the expression of target genes including the cell cycle gene p21, leading to cell cycle arrest and apoptosis...
- Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium studySam J Lubner
University of Wisconsin, Madison, WI 53792, USA
J Clin Oncol 28:3491-7. 2010..Secondary end points included overall survival (OS), time to progression (TTP), VEGF levels, and molecular studies of EGFR and k-ras...
- A preclinical and clinical study of lithium in low-grade neuroendocrine tumorsSam J Lubner
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA
Oncologist 16:452-7. 2011..Use of lithium chloride in murine models suppressed carcinoid cell growth, reduced GSK-3β levels, and reduced expression of chromogranin A. This study assessed the efficacy of lithium chloride in patients with NETs...
- A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network studyNoelle K Loconte
University of Wisconsin Carbone Cancer Center and the University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, K6 548 CSC, Madison, WI 53792, USA
Invest New Drugs 31:943-8. 2013..The recommended phase II dose of sorafenib in combination with 2DOC is 200 mg BID. There were infrequent grade 3 toxicities, most evident with sorafenib at 400 mg BID...
- Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapyNoelle K Loconte
University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Ave, CSC K4 548, Madison, WI 53792, USA
Cancer Chemother Pharmacol 65:775-80. 2010..The goal of this study was to identify clinical and nonclinical factors which were associated with the development of DLT in phase I studies...
- A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreasSteven Attia
University of Wisconsin Paul P Carbone Comprehensive Cancer Center, 600 Highland Avenue, K4 528, Madison, WI 53792, USA
Invest New Drugs 26:369-79. 2008..In conclusion, this regimen appears inactive against predominantly GR pancreatic cancer. RR M2 protein may not have a critical role in the malignant potential of pancreatic cancer...
- Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinomaSteven Attia
Department of Medicine, Section of Hematology and Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA
Clin Adv Hematol Oncol 6:44-54. 2008..Animal models suggest that growth hormone participates in hepatocarcinogenesis...
- Guillain-Barré syndrome after treatment with sunitinib malate?Brian Mulherin
Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin, Paul P Carbone Comprehensive Cancer Center, Madison, USA
Oncology (Williston Park) 22:66-7, 70-1. 2008..This is the first report of such an effect. The literature on chemotherapy-induced Guillain-Barri syndrome is also reviewed. Oncology providers should be aware of this rare but potentially serious possible adverse effect of sunitinib...
- Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with TriapineJill M Kolesar
University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin Madison, 600 Highland Avenue, Room K4 554, Madison, WI 53792, USA
J Inorg Biochem 102:693-8. 2008..A potential source for the increase in the heme signal is cytochrome c released from the mitochondria. These results provide valuable insight into the in vivo mechanism of action of Triapine...
- Target practice: figuring out which, when, and why to use systemic therapies for metastatic colon cancerKyle D Holen
University of Wisconsin Comprehensive Cancer Center, Madison, 53792, USA
Cancer Invest 24:98-105. 2006..Although the decision regarding colorectal cancer chemotherapy is now more complicated, our patients have certainly benefited from better response rates and most importantly, longer survival times...